Testing effectiveness (Phase 2)Ended earlyNCT03552692
What this trial is testing
Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma
Who this might be right for
T-Cell Lymphoma RelapsedT-Cell Lymphoma Refractory
Fondazione Italiana Linfomi - ETS 22